(Q38195440)

30 August 2017

1 reference

title

SGLT inhibitors in management of diabetes (English)

1 reference

30 August 2017

3

1 reference

30 August 2017

Abd A Tahrani

1

0 references

author name string

Anthony H Barnett

series ordinal

2

1 reference

30 August 2017

13 August 2013

1 reference

The Lancet: Diabetes & Endocrinology

30 August 2017

1 reference

30 August 2017

1

1 reference

30 August 2017

2

1 reference

30 August 2017

140-151

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

The challenge of managing coexistent type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Molecular physiology of sodium-glucose cotransporters

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Biology of human sodium glucose transporters

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Molecular biology of mammalian glucose transporters

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Active sugar transport in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Glucose sensing and signalling; regulation of intestinal glucose transport

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Normal kinetics of intestinal glucose absorption in the absence of GLUT2: evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Expression of monosaccharide transporters in intestine of diabetic humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Glucose-galactose malabsorption. Report of a case with autoradiographic studies of a mucosal biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Renal gluconeogenesis: its importance in human glucose homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

The proximal tubule in the pathophysiology of the diabetic kidney

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

1 reference

7 January 2021

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Effects of SGLT2 inhibitors on cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Interpreting adverse signals in diabetes drug development programs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970050-0

7 January 2021

10.1016/S2213-8587(13)70050-0

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24622320